---
inFeed: true
hasPage: false
inNav: false
isBasedOnUrl: 'http://www.xconomy.com/boston/2016/02/05/east-coast-bio-roundup-crispr-tessier-lavigne-pricing-spero-more/?utm_content=buffer8b179&utm_medium=social&utm_source=linkedin.com&utm_campaign=buffer'
inLanguage: en
starred: false
keywords:
  - mersana
  - kadmon
  - therapeutics
  - biotech
  - editas
  - ma-based
  - nasdaq
  - gene
  - boston
  - therapies
description: 'Xconomy Boston - There was biotech news up and down the East Coast this week. In Boston, all eyes were on the first biotech IPO of the year-and the sector let out a collective sigh when things went well.'
datePublished: '2016-02-16T20:04:48.822Z'
dateModified: '2016-02-16T20:04:47.474Z'
author:
  - name: Ben Fidler
    url: 'http://www.xconomy.com/author/bfidler/'
    avatar: {}
related: []
app_links: []
title: Editas Medicine IPO
sourcePath: _posts/2016-02-16-editas-medicine-ipo.md
published: true
authors: []
publisher:
  name: Xconomy
  domain: www.xconomy.com
  url: 'http://www.xconomy.com'
  favicon: 'http://www.xconomy.com/wordpress/wp-content/themes/xconomy/images/favicon.ico'
_context: 'http://schema.org'
_type: MediaObject

---
# Editas Medicine IPO

<article style=""><h1>East Coast Bio Roundup: CRISPR, Tessier-Lavigne, Pricing, Spero &amp; More | Xconomy</h1><img src="https://s3-us-west-2.amazonaws.com/the-grid-img/p/23eceb32c188bec728438a6d9494be95ee473054.jpg" /></article>